Carfilzomib vs TQB3602

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: Proteasome · full Multiple Myeloma pipeline

Carfilzomib

Marketed by Amgen and partners

Approved in Multiple Myelomasmall molecule
Partial signal

NCT01080391 · Phase 3 · completed

The 792 participants were randomly assigned to carfilzomib plus lenalidomide and dexamethasone or to lenalidomide and dexamethasone, but treatment was open-label rather than blinded. The primary clinical endpoint, progression-free survival, was met, with a median of 26.3 versus 17.6 months and a statistically significant difference (p<0.0001).

Next expected readout: November 2026 · NCT04973605 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Kd - Carfilzomib and Dexamethasone — Participants with PFS events: 68 Participants; Participants who were censored: 86 Participants | KdD - Carfilzomib, Dexamethasone and Daratumumab — Participants with PFS events: 110 Participants; Participants who were censored: 202 Participants (met)

Result source: NCT03158688

TQB3602

Developed by Sino Biopharmaceutical

Phase 1 in Multiple Myelomasmall molecule
Weak signal

NCT04275583 · Phase 1 · status unknown

This is a small, open-label, single-arm, non-randomized dose-finding study designed to establish tolerability rather than to test clinical benefit, with no comparator arm and no blinding. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

These results cover the 25-patient dose-escalation phase; the study's dose-expansion phase is not included.

Reported efficacy

Dose-limiting toxicity (DLT) (Baseline up to 28 days): Twenty-five patients with relapsed/refractory multiple myeloma who had relapsed or failed at least 2 lines of therapy were enrolled in the dose-escalation phase. Two patients in the 7.0 mg dose group developed dose-limiting toxicities, giving a maximum tolerated dose of 6.0 mg. Any-grade adverse events occurred in 24 (96.0%) patients and grade >=3 adverse events in 13 (52.0%). Among 22 response-evaluable patients, 63.7% achieved stable disease or better.

Result source: NCT04275583

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCarfilzomibTQB3602
PFS, median26.3 vs 17.6vs Lenalidomide and Dexamethasone (Rd)n 396NCT01080391
35 other results
  • 35.6 vs 19.1 n 179 · Phase 3 · primary NCT03275285
  • 41.7 vs 20.8 n 179 · Phase 3 · primary NCT03275285
  • 18.7 vs 9.4 n 464 · Phase 3 · primary NCT01568866
  • 22.3 vs 22.1 n 478 · Phase 3 · primary NCT01818752
  • 11.2 20/70 mg/m² once weekly · n 240 · Phase 3 · primary NCT02412878
  • 7.6 20/27 mg/m² twice weekly · n 238 · Phase 3 · primary NCT02412878
  • 3.7 vs 3.3 n 157 · Phase 3 · secondary NCT01302392
  • 5 low-dose · n 64 · Phase 2 · primary NCT01903811
  • 8 high-dose · n 57 · Phase 2 · primary NCT01903811
  • 15.3 70 mg/m² · n 89 · Phase 1/2 · secondary NCT01677858
  • 16.2 70 mg/m² · n 104 · Phase 1/2 · secondary NCT01677858
  • 3.7 n 257 · Phase 2 · secondary NCT00511238
  • 6.9 20/56 mg/m² · n 24 · Phase 1/2 · secondary NCT00531284
  • 1.8 20/36 mg/m² Bolus · n 65 · Phase 1/2 · secondary NCT00531284
  • 4.6 20 mg/m² · n 35 · Phase 2 · secondary NCT00530816
  • 8.2 20 mg/m² · n 59 · Phase 2 · secondary NCT00530816
  • 3.5 n 42 · Phase 2 · secondary NCT00511238
  • 12.9 88 mg/m² · n 6 · Phase 1/2 · secondary NCT01677858
  • 1.6 20/70 mg/m² · n 11 · Phase 1/2 · secondary NCT00531284
  • 21 70 mg/m² · n 15 · Phase 1/2 · secondary NCT01677858
  • 1.5 20/56 mg/m² · n 10 · Phase 1/2 · secondary NCT00531284
  • 1 20/70 mg/m² · n 3 · Phase 1/2 · secondary NCT00531284
  • 11.5 20/56 mg/m² + Dex · n 8 · Phase 1/2 · secondary NCT00531284
  • 2.9 45 mg/m² · n 7 · Phase 1/2 · secondary NCT00531284
  • 1.4 20/45 mg/m² · n 6 · Phase 1/2 · secondary NCT00531284
  • 4.6 20/45 mg/m² + Dex · n 14 · Phase 1/2 · secondary NCT00531284
  • 4.6 20/45 mg/m² · n 3 · Phase 1/2 · secondary NCT00531284
  • 1.8 20/36 mg/m² Bolus · n 7 · Phase 1/2 · secondary NCT00531284
  • 1.7 36 mg/m² · n 6 · Phase 1/2 · secondary NCT00531284
  • 3.8 n 12 · Phase 2 · secondary NCT01775553
  • 9.4 20/70 mg/m² · n 2 · Phase 1/2 · secondary NCT00531284
  • 13.6 45 mg/m² · n 3 · Phase 1/2 · secondary NCT01677858
  • 5.2 20/36 mg/m² · n 4 · Phase 1/2 · secondary NCT00531284
  • 1.8 20/27 mg/m² Bolus · n 4 · Phase 1/2 · secondary NCT00531284
  • 5.1 20 mg/m² Bolus · n 3 · Phase 1/2 · secondary NCT00531284
—Not reported
OS, median10.2 vs 10+0.2 vs placebon 157NCT01302392
10 other results
—Not reported
ORR82.5%b20/56 mg/m^2 once weekly · n 228NCT03859427
56 other results
  • 86.3% 20/27 mg/m^2 twice weekly · n 226 · Phase 3 · primary NCT03859427
  • 35.8% wk 24 · n 123 · Phase 3 · primary NCT03029234
  • 87.1% vs 66.7% n 396 · Phase 3 · secondary NCT01080391
  • 86.6% vs 82.9% n 179 · Phase 3 · secondary NCT03275285
  • 76.9% vs 62.6% n 464 · Phase 3 · secondary NCT01568866
  • 84.3% vs 74.7% n 312 · Phase 3 · secondary NCT03158688
  • 84.3% vs 78.8% n 478 · Phase 3 · secondary NCT01818752
  • 62.9% 20/70 mg/m² once weekly · n 240 · Phase 3 · secondary NCT02412878
  • 40.8% 20/27 mg/m² twice weekly · n 238 · Phase 3 · secondary NCT02412878
  • 35.8% wk 48 · n 123 · Phase 3 · secondary NCT03029234
  • 35% wk 48 · n 123 · Phase 3 · secondary NCT03029234
  • 35% wk 24 · n 123 · Phase 3 · secondary NCT03029234
  • 74.2% 70 mg/m² · n 89 · Phase 1/2 · primary NCT01677858
  • 76.9% 70 mg/m² · n 104 · Phase 1/2 · primary NCT01677858
  • 15.4% 20/36 mg/m² Bolus · wk 16 · n 65 · Phase 1/2 · primary NCT00531284
  • 53% 20/27 mg/m² · n 66 · Phase 2 · primary NCT00530816
  • 16.1% 20 mg/m² · n 31 · Phase 2 · primary NCT00530816
  • 39.6% 20 mg/m² · n 53 · Phase 2 · primary NCT00530816
  • 88.1% n 67 · Phase 2 · primary NCT03412565
  • 90.8% n 65 · Phase 2 · primary NCT03412565
  • 84.8% n 66 · Phase 2 · primary NCT03412565
  • 66.7% 88 mg/m² · n 6 · Phase 1/2 · primary NCT01677858
  • 93.3% 70 mg/m² · n 15 · Phase 1/2 · primary NCT01677858
  • 100% 56 mg/m² · n 3 · Phase 1/2 · primary NCT01677858
  • 33.3% 45 mg/m² · n 3 · Phase 1/2 · primary NCT01677858
  • 50% 20/56 mg/m² · n 24 · Phase 1/2 · secondary NCT00531284
  • 38.5% 20/36 mg/m² Bolus · n 65 · Phase 1/2 · secondary NCT00531284
  • 52.2% 20/27 mg/m² · n 67 · Phase 2 · secondary NCT00530816
  • 17.1% 20 mg/m² · n 35 · Phase 2 · secondary NCT00530816
  • 42.4% 20 mg/m² · n 59 · Phase 2 · secondary NCT00530816
  • 97% n 67 · Phase 2 · secondary NCT03412565
  • 59.2% n 49 · Phase 4 · secondary NCT03934684
  • 53.8% n 52 · Phase 4 · secondary NCT03934684
  • 97.8% n 45 · Phase 2 · secondary NCT01402284
  • 36.4% 20/70 mg/m² · n 11 · Phase 1/2 · secondary NCT00531284
  • 10% 20/56 mg/m² · n 10 · Phase 1/2 · secondary NCT00531284
  • 0% 20/70 mg/m² · n 3 · Phase 1/2 · secondary NCT00531284
  • 100% 20/70 mg/m² · n 4 · Phase 1/2 · secondary NCT00531284
  • 37.5% 20/56 mg/m² + Dex · n 8 · Phase 1/2 · secondary NCT00531284
  • 28.6% 45 mg/m² · n 7 · Phase 1/2 · secondary NCT00531284
  • 50% 20/45 mg/m² · n 6 · Phase 1/2 · secondary NCT00531284
  • 64.3% 20/45 mg/m² + Dex · n 14 · Phase 1/2 · secondary NCT00531284
  • 25% n 8 · Phase 2 · secondary NCT00721734
  • 37.5% n 8 · Phase 2 · secondary NCT00721734
  • 50% 20/70 mg/m² · n 2 · Phase 1/2 · secondary NCT00531284
  • 0% 20/56 mg/m² · n 2 · Phase 1/2 · secondary NCT00531284
  • 33.3% 20/45 mg/m² · n 3 · Phase 1/2 · secondary NCT00531284
  • 42.9% 20/36 mg/m² Bolus · n 7 · Phase 1/2 · secondary NCT00531284
  • 33.3% 36 mg/m² · n 6 · Phase 1/2 · secondary NCT00531284
  • 50% 20/36 mg/m² · n 4 · Phase 1/2 · secondary NCT00531284
  • 0% 20/27 mg/m² Bolus · n 4 · Phase 1/2 · secondary NCT00531284
  • 18.2% n 11 · Phase 2 · secondary NCT00721734
  • 27.3% n 11 · Phase 2 · secondary NCT00721734
  • 22.2% n 9 · Phase 2 · secondary NCT00721734
  • 100% 20 mg/m² Bolus · n 3 · Phase 1/2 · secondary NCT00531284
  • 100% 20/56 mg/m² · n 1 · Phase 1/2 · secondary NCT00531284
—Not reported
VGPR or better72.6% vs 56.1%vs Carfilzomib + Dexamethasonen 179NCT03275285
4 other results
—Not reported
MRD negativity18.3% vs 5.2%vs Carfilzomib and Dexamethasonewk 52 · n 312NCT03158688
6 other results
  • 18.9% 20/56 mg/m^2 once weekly · wk 52 · n 228 · Phase 3 · secondary NCT03859427
  • 18.1% 20/27 mg/m^2 twice weekly · wk 52 · n 226 · Phase 3 · secondary NCT03859427
  • 44.4% wk 14 · n 45 · Phase 2 · secondary NCT01402284
  • 25.4% n 67 · Phase 2 · secondary NCT03412565
  • 21.5% n 65 · Phase 2 · secondary NCT03412565
  • 27.3% n 66 · Phase 2 · secondary NCT03412565
—Not reported

PFS, median

Carfilzomib
26.3 vs 17.6vs Lenalidomide and Dexamethasone (Rd)n 396NCT01080391
35 other results
  • 35.6 vs 19.1 n 179 · Phase 3 · primary NCT03275285
  • 41.7 vs 20.8 n 179 · Phase 3 · primary NCT03275285
  • 18.7 vs 9.4 n 464 · Phase 3 · primary NCT01568866
  • 22.3 vs 22.1 n 478 · Phase 3 · primary NCT01818752
  • 11.2 20/70 mg/m² once weekly · n 240 · Phase 3 · primary NCT02412878
  • 7.6 20/27 mg/m² twice weekly · n 238 · Phase 3 · primary NCT02412878
  • 3.7 vs 3.3 n 157 · Phase 3 · secondary NCT01302392
  • 5 low-dose · n 64 · Phase 2 · primary NCT01903811
  • 8 high-dose · n 57 · Phase 2 · primary NCT01903811
  • 15.3 70 mg/m² · n 89 · Phase 1/2 · secondary NCT01677858
  • 16.2 70 mg/m² · n 104 · Phase 1/2 · secondary NCT01677858
  • 3.7 n 257 · Phase 2 · secondary NCT00511238
  • 6.9 20/56 mg/m² · n 24 · Phase 1/2 · secondary NCT00531284
  • 1.8 20/36 mg/m² Bolus · n 65 · Phase 1/2 · secondary NCT00531284
  • 4.6 20 mg/m² · n 35 · Phase 2 · secondary NCT00530816
  • 8.2 20 mg/m² · n 59 · Phase 2 · secondary NCT00530816
  • 3.5 n 42 · Phase 2 · secondary NCT00511238
  • 12.9 88 mg/m² · n 6 · Phase 1/2 · secondary NCT01677858
  • 1.6 20/70 mg/m² · n 11 · Phase 1/2 · secondary NCT00531284
  • 21 70 mg/m² · n 15 · Phase 1/2 · secondary NCT01677858
  • 1.5 20/56 mg/m² · n 10 · Phase 1/2 · secondary NCT00531284
  • 1 20/70 mg/m² · n 3 · Phase 1/2 · secondary NCT00531284
  • 11.5 20/56 mg/m² + Dex · n 8 · Phase 1/2 · secondary NCT00531284
  • 2.9 45 mg/m² · n 7 · Phase 1/2 · secondary NCT00531284
  • 1.4 20/45 mg/m² · n 6 · Phase 1/2 · secondary NCT00531284
  • 4.6 20/45 mg/m² + Dex · n 14 · Phase 1/2 · secondary NCT00531284
  • 4.6 20/45 mg/m² · n 3 · Phase 1/2 · secondary NCT00531284
  • 1.8 20/36 mg/m² Bolus · n 7 · Phase 1/2 · secondary NCT00531284
  • 1.7 36 mg/m² · n 6 · Phase 1/2 · secondary NCT00531284
  • 3.8 n 12 · Phase 2 · secondary NCT01775553
  • 9.4 20/70 mg/m² · n 2 · Phase 1/2 · secondary NCT00531284
  • 13.6 45 mg/m² · n 3 · Phase 1/2 · secondary NCT01677858
  • 5.2 20/36 mg/m² · n 4 · Phase 1/2 · secondary NCT00531284
  • 1.8 20/27 mg/m² Bolus · n 4 · Phase 1/2 · secondary NCT00531284
  • 5.1 20 mg/m² Bolus · n 3 · Phase 1/2 · secondary NCT00531284
TQB3602
—Not reported

OS, median

Carfilzomib
10.2 vs 10+0.2 vs placebon 157NCT01302392
10 other results
TQB3602
—Not reported

ORR

Carfilzomib
82.5%b20/56 mg/m^2 once weekly · n 228NCT03859427
56 other results
  • 86.3% 20/27 mg/m^2 twice weekly · n 226 · Phase 3 · primary NCT03859427
  • 35.8% wk 24 · n 123 · Phase 3 · primary NCT03029234
  • 87.1% vs 66.7% n 396 · Phase 3 · secondary NCT01080391
  • 86.6% vs 82.9% n 179 · Phase 3 · secondary NCT03275285
  • 76.9% vs 62.6% n 464 · Phase 3 · secondary NCT01568866
  • 84.3% vs 74.7% n 312 · Phase 3 · secondary NCT03158688
  • 84.3% vs 78.8% n 478 · Phase 3 · secondary NCT01818752
  • 62.9% 20/70 mg/m² once weekly · n 240 · Phase 3 · secondary NCT02412878
  • 40.8% 20/27 mg/m² twice weekly · n 238 · Phase 3 · secondary NCT02412878
  • 35.8% wk 48 · n 123 · Phase 3 · secondary NCT03029234
  • 35% wk 48 · n 123 · Phase 3 · secondary NCT03029234
  • 35% wk 24 · n 123 · Phase 3 · secondary NCT03029234
  • 74.2% 70 mg/m² · n 89 · Phase 1/2 · primary NCT01677858
  • 76.9% 70 mg/m² · n 104 · Phase 1/2 · primary NCT01677858
  • 15.4% 20/36 mg/m² Bolus · wk 16 · n 65 · Phase 1/2 · primary NCT00531284
  • 53% 20/27 mg/m² · n 66 · Phase 2 · primary NCT00530816
  • 16.1% 20 mg/m² · n 31 · Phase 2 · primary NCT00530816
  • 39.6% 20 mg/m² · n 53 · Phase 2 · primary NCT00530816
  • 88.1% n 67 · Phase 2 · primary NCT03412565
  • 90.8% n 65 · Phase 2 · primary NCT03412565
  • 84.8% n 66 · Phase 2 · primary NCT03412565
  • 66.7% 88 mg/m² · n 6 · Phase 1/2 · primary NCT01677858
  • 93.3% 70 mg/m² · n 15 · Phase 1/2 · primary NCT01677858
  • 100% 56 mg/m² · n 3 · Phase 1/2 · primary NCT01677858
  • 33.3% 45 mg/m² · n 3 · Phase 1/2 · primary NCT01677858
  • 50% 20/56 mg/m² · n 24 · Phase 1/2 · secondary NCT00531284
  • 38.5% 20/36 mg/m² Bolus · n 65 · Phase 1/2 · secondary NCT00531284
  • 52.2% 20/27 mg/m² · n 67 · Phase 2 · secondary NCT00530816
  • 17.1% 20 mg/m² · n 35 · Phase 2 · secondary NCT00530816
  • 42.4% 20 mg/m² · n 59 · Phase 2 · secondary NCT00530816
  • 97% n 67 · Phase 2 · secondary NCT03412565
  • 59.2% n 49 · Phase 4 · secondary NCT03934684
  • 53.8% n 52 · Phase 4 · secondary NCT03934684
  • 97.8% n 45 · Phase 2 · secondary NCT01402284
  • 36.4% 20/70 mg/m² · n 11 · Phase 1/2 · secondary NCT00531284
  • 10% 20/56 mg/m² · n 10 · Phase 1/2 · secondary NCT00531284
  • 0% 20/70 mg/m² · n 3 · Phase 1/2 · secondary NCT00531284
  • 100% 20/70 mg/m² · n 4 · Phase 1/2 · secondary NCT00531284
  • 37.5% 20/56 mg/m² + Dex · n 8 · Phase 1/2 · secondary NCT00531284
  • 28.6% 45 mg/m² · n 7 · Phase 1/2 · secondary NCT00531284
  • 50% 20/45 mg/m² · n 6 · Phase 1/2 · secondary NCT00531284
  • 64.3% 20/45 mg/m² + Dex · n 14 · Phase 1/2 · secondary NCT00531284
  • 25% n 8 · Phase 2 · secondary NCT00721734
  • 37.5% n 8 · Phase 2 · secondary NCT00721734
  • 50% 20/70 mg/m² · n 2 · Phase 1/2 · secondary NCT00531284
  • 0% 20/56 mg/m² · n 2 · Phase 1/2 · secondary NCT00531284
  • 33.3% 20/45 mg/m² · n 3 · Phase 1/2 · secondary NCT00531284
  • 42.9% 20/36 mg/m² Bolus · n 7 · Phase 1/2 · secondary NCT00531284
  • 33.3% 36 mg/m² · n 6 · Phase 1/2 · secondary NCT00531284
  • 50% 20/36 mg/m² · n 4 · Phase 1/2 · secondary NCT00531284
  • 0% 20/27 mg/m² Bolus · n 4 · Phase 1/2 · secondary NCT00531284
  • 18.2% n 11 · Phase 2 · secondary NCT00721734
  • 27.3% n 11 · Phase 2 · secondary NCT00721734
  • 22.2% n 9 · Phase 2 · secondary NCT00721734
  • 100% 20 mg/m² Bolus · n 3 · Phase 1/2 · secondary NCT00531284
  • 100% 20/56 mg/m² · n 1 · Phase 1/2 · secondary NCT00531284
TQB3602
—Not reported

VGPR or better

Carfilzomib
72.6% vs 56.1%vs Carfilzomib + Dexamethasonen 179NCT03275285
4 other results
TQB3602
—Not reported

MRD negativity

Carfilzomib
18.3% vs 5.2%vs Carfilzomib and Dexamethasonewk 52 · n 312NCT03158688
6 other results
  • 18.9% 20/56 mg/m^2 once weekly · wk 52 · n 228 · Phase 3 · secondary NCT03859427
  • 18.1% 20/27 mg/m^2 twice weekly · wk 52 · n 226 · Phase 3 · secondary NCT03859427
  • 44.4% wk 14 · n 45 · Phase 2 · secondary NCT01402284
  • 25.4% n 67 · Phase 2 · secondary NCT03412565
  • 21.5% n 65 · Phase 2 · secondary NCT03412565
  • 27.3% n 66 · Phase 2 · secondary NCT03412565
TQB3602
—Not reported
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

TQB3602
Twenty-five patients with relapsed/refractory multiple myeloma who had relapsed or failed at least 2 lines of therapy were enrolled in the dose-escalation phase. Two patients in the 7.0 mg dose group developed dose-limiting toxicities, giving a maximum tolerated dose of 6.0 mg. Any-grade adverse events occurred in 24 (96.0%) patients and grade >=3 adverse events in 13 (52.0%). Among 22 response-evaluable patients, 63.7% achieved stable disease or better. NCT04275583 · Phase 1 · design grade: weak · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Carfilzomib: 4 of 4 rows · TQB3602: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCarfilzomib
Dropout rate
1%a
NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3
show 68 more results
0.6%
NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3
n/a: no completion milestone
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
—Carfilzomib
NCT01568866 · Phase 3
89.7%Carfilzomib + DEX
NCT01568866 · Phase 3 · combination
5.4%20/70 mg/m² once weekly
NCT02412878 · Phase 3 · combination
8.8%20/27 mg/m² twice weekly
NCT02412878 · Phase 3 · combination
67.3%
NCT03158688 · Phase 3 · combination
71.6%D + Bortezomib + Melphalan + Predn
NCT03412565 · Phase 2 · combination
1.5%Daratumumab (D)+Bortezomib+Lenalid
NCT03412565 · Phase 2 · combination
77.3%Daratumumab + Carfilzomib + Dexame
NCT03412565 · Phase 2 · combination
78.5%Daratumumab + Lenalidomide + Dexam
NCT03412565 · Phase 2 · combination
57.1%20/70 mg/m²
NCT00531284 · Phase 1/2
100%20/70 mg/m²
NCT00531284 · Phase 1/2
100%20/70 mg/m²
NCT00531284 · Phase 1/2
100%20/56 mg/m²
NCT00531284 · Phase 1/2
100%20/56 mg/m² + Dex
NCT00531284 · Phase 1/2 · combination
100%20/56 mg/m²
NCT00531284 · Phase 1/2
100%20/56 mg/m²
NCT00531284 · Phase 1/2
100%20/45 mg/m²
NCT00531284 · Phase 1/2
85.7%20/45 mg/m² + Dex
NCT00531284 · Phase 1/2 · combination
100%20/45 mg/m²
NCT00531284 · Phase 1/2
100%45 mg/m²
NCT00531284 · Phase 1/2
100%20/36 mg/m²
NCT00531284 · Phase 1/2
85.7%20/36 mg/m² Bolus
NCT00531284 · Phase 1/2
100%36 mg/m²
NCT00531284 · Phase 1/2
96.9%20/36 mg/m² Bolus
NCT00531284 · Phase 1/2
100%20/27 mg/m² Bolus
NCT00531284 · Phase 1/2
100%20 mg/m² Bolus
NCT00531284 · Phase 1/2
91.3%Carfilzomib (A0)
NCT00511238 · Phase 2
85%Carfilzomib (A1)
NCT00511238 · Phase 2 · pooled
58.6%20/27 mg/m²
NCT00530816 · Phase 2 · pooled
74.3%20 mg/m²
NCT00530816 · Phase 2
71.2%20 mg/m²
NCT00530816 · Phase 2
92.3%Carfilzomib and Dexamethasone (Kd)
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
65.3%Carfilzomib, Lenalidomide and Dexa
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
16.2%20/56 mg/m^2 once weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
—20/27 mg/m^2 twice weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
78.6%
NCT03029234 · Phase 3 · registry result, not featured evidence · combination
41.4%
NCT01818752 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02969837 · Phase 2 · registry result, not featured evidence
—
NCT01402284 · Phase 2 · registry result, not featured evidence · combination
11.1%low-dose
NCT01903811 · Phase 2 · registry result, not featured evidence · combination
19.7%high-dose
NCT01903811 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT01775553 · Phase 2 · registry result, not featured evidence
20.5%
NCT01351623 · Phase 2 · registry result, not featured evidence
75%Carfilzomib - Dialysis
NCT00721734 · Phase 2 · registry result, not featured evidence
100%Carfilzomib - Mild RI
NCT00721734 · Phase 2 · registry result, not featured evidence
80%Carfilzomib - Moderate RI
NCT00721734 · Phase 2 · registry result, not featured evidence
66.7%Carfilzomib - Normal RF
NCT00721734 · Phase 2 · registry result, not featured evidence
75%Carfilzomib - Severe RI
NCT00721734 · Phase 2 · registry result, not featured evidence
0%56mg/m2/Dose
NCT02937571 · Phase 1/2 · registry result, not featured evidence
0%45mg/m2/Dose
NCT02937571 · Phase 1/2 · registry result, not featured evidence
—MTD: Carfilzomib
NCT02937571 · Phase 1/2 · registry result, not featured evidence
0%Dose Level 0
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
0%Dose Level 1
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
0%Dose Level 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
0%Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 0
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 1
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
2.8%Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
100%88 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
93.3%70 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
95.5%70 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
66.7%56 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
100%45 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3
show 68 more results
—
NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3
16.2%
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
—Carfilzomib
NCT01568866 · Phase 3
20.7%Carfilzomib + DEX
NCT01568866 · Phase 3 · combination
—20/70 mg/m² once weekly
NCT02412878 · Phase 3 · combination
—20/27 mg/m² twice weekly
NCT02412878 · Phase 3 · combination
—
NCT03158688 · Phase 3 · combination
—D + Bortezomib + Melphalan + Predn
NCT03412565 · Phase 2 · combination
—Daratumumab (D)+Bortezomib+Lenalid
NCT03412565 · Phase 2 · combination
—Daratumumab + Carfilzomib + Dexame
NCT03412565 · Phase 2 · combination
—Daratumumab + Lenalidomide + Dexam
NCT03412565 · Phase 2 · combination
14.3%20/70 mg/m²
NCT00531284 · Phase 1/2
0%20/70 mg/m²
NCT00531284 · Phase 1/2
27.3%20/70 mg/m²
NCT00531284 · Phase 1/2
33.3%20/56 mg/m²
NCT00531284 · Phase 1/2
25%20/56 mg/m² + Dex
NCT00531284 · Phase 1/2 · combination
20%20/56 mg/m²
NCT00531284 · Phase 1/2
20.8%20/56 mg/m²
NCT00531284 · Phase 1/2
0%20/45 mg/m²
NCT00531284 · Phase 1/2
0%20/45 mg/m² + Dex
NCT00531284 · Phase 1/2 · combination
50%20/45 mg/m²
NCT00531284 · Phase 1/2
28.6%45 mg/m²
NCT00531284 · Phase 1/2
0%20/36 mg/m²
NCT00531284 · Phase 1/2
14.3%20/36 mg/m² Bolus
NCT00531284 · Phase 1/2
0%36 mg/m²
NCT00531284 · Phase 1/2
10.8%20/36 mg/m² Bolus
NCT00531284 · Phase 1/2
25%20/27 mg/m² Bolus
NCT00531284 · Phase 1/2
0%20 mg/m² Bolus
NCT00531284 · Phase 1/2
28.3%Carfilzomib (A0)
NCT00511238 · Phase 2
12.4%Carfilzomib (A1)
NCT00511238 · Phase 2 · pooled
10%20/27 mg/m²
NCT00530816 · Phase 2 · pooled
17.1%20 mg/m²
NCT00530816 · Phase 2
22%20 mg/m²
NCT00530816 · Phase 2
—Carfilzomib and Dexamethasone (Kd)
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
—Carfilzomib, Lenalidomide and Dexa
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
—20/56 mg/m^2 once weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
—20/27 mg/m^2 twice weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
—
NCT03029234 · Phase 3 · registry result, not featured evidence · combination
15.5%
NCT01818752 · Phase 3 · registry result, not featured evidence · combination
—
NCT02969837 · Phase 2 · registry result, not featured evidence
—
NCT01402284 · Phase 2 · registry result, not featured evidence · combination
—low-dose
NCT01903811 · Phase 2 · registry result, not featured evidence · combination
—high-dose
NCT01903811 · Phase 2 · registry result, not featured evidence · combination
7.7%
NCT01775553 · Phase 2 · registry result, not featured evidence
9.1%
NCT01351623 · Phase 2 · registry result, not featured evidence
37.5%Carfilzomib - Dialysis
NCT00721734 · Phase 2 · registry result, not featured evidence
8.3%Carfilzomib - Mild RI
NCT00721734 · Phase 2 · registry result, not featured evidence
40%Carfilzomib - Moderate RI
NCT00721734 · Phase 2 · registry result, not featured evidence
25%Carfilzomib - Normal RF
NCT00721734 · Phase 2 · registry result, not featured evidence
0%Carfilzomib - Severe RI
NCT00721734 · Phase 2 · registry result, not featured evidence
0%56mg/m2/Dose
NCT02937571 · Phase 1/2 · registry result, not featured evidence
0%45mg/m2/Dose
NCT02937571 · Phase 1/2 · registry result, not featured evidence
—MTD: Carfilzomib
NCT02937571 · Phase 1/2 · registry result, not featured evidence
—Dose Level 0
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 1
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 0
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 1
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
50%88 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
13.3%70 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
14.6%70 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
0%56 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
0%45 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
Serious AEs
65.3%a
NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3
show 68 more results
58.6%
NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3
72.9%
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
58.7%Carfilzomib
NCT01568866 · Phase 3
—Carfilzomib + DEX
NCT01568866 · Phase 3 · combination
49.6%20/70 mg/m² once weekly
NCT02412878 · Phase 3 · combination
43.4%20/27 mg/m² twice weekly
NCT02412878 · Phase 3 · combination
68.5%
NCT03158688 · Phase 3 · combination
44.8%D + Bortezomib + Melphalan + Predn
NCT03412565 · Phase 2 · combination
28.4%Daratumumab (D)+Bortezomib+Lenalid
NCT03412565 · Phase 2 · combination
33.3%Daratumumab + Carfilzomib + Dexame
NCT03412565 · Phase 2 · combination
56.9%Daratumumab + Lenalidomide + Dexam
NCT03412565 · Phase 2 · combination
71.4%20/70 mg/m²
NCT00531284 · Phase 1/2
100%20/70 mg/m²
NCT00531284 · Phase 1/2
54.5%20/70 mg/m²
NCT00531284 · Phase 1/2
33.3%20/56 mg/m²
NCT00531284 · Phase 1/2
37.5%20/56 mg/m² + Dex
NCT00531284 · Phase 1/2 · combination
50%20/56 mg/m²
NCT00531284 · Phase 1/2
45.8%20/56 mg/m²
NCT00531284 · Phase 1/2
0%20/45 mg/m²
NCT00531284 · Phase 1/2
35.7%20/45 mg/m² + Dex
NCT00531284 · Phase 1/2 · combination
83.3%20/45 mg/m²
NCT00531284 · Phase 1/2
57.1%45 mg/m²
NCT00531284 · Phase 1/2
50%20/36 mg/m²
NCT00531284 · Phase 1/2
57.1%20/36 mg/m² Bolus
NCT00531284 · Phase 1/2
33.3%36 mg/m²
NCT00531284 · Phase 1/2
41.5%20/36 mg/m² Bolus
NCT00531284 · Phase 1/2
25%20/27 mg/m² Bolus
NCT00531284 · Phase 1/2
33.3%20 mg/m² Bolus
NCT00531284 · Phase 1/2
43.5%Carfilzomib (A0)
NCT00511238 · Phase 2
47.4%Carfilzomib (A1)
NCT00511238 · Phase 2 · pooled
38.6%20/27 mg/m²
NCT00530816 · Phase 2 · pooled
34.3%20 mg/m²
NCT00530816 · Phase 2
30.5%20 mg/m²
NCT00530816 · Phase 2
38.5%Carfilzomib and Dexamethasone (Kd)
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
22.4%Carfilzomib, Lenalidomide and Dexa
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
37.7%20/56 mg/m^2 once weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
32.5%20/27 mg/m^2 twice weekly
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
55.3%
NCT03029234 · Phase 3 · registry result, not featured evidence · combination
49.6%
NCT01818752 · Phase 3 · registry result, not featured evidence · combination
39.1%
NCT02969837 · Phase 2 · registry result, not featured evidence
42.2%
NCT01402284 · Phase 2 · registry result, not featured evidence · combination
39.4%low-dose
NCT01903811 · Phase 2 · registry result, not featured evidence · combination
47.4%high-dose
NCT01903811 · Phase 2 · registry result, not featured evidence · combination
23.1%
NCT01775553 · Phase 2 · registry result, not featured evidence
63.6%
NCT01351623 · Phase 2 · registry result, not featured evidence
100%Carfilzomib - Dialysis
NCT00721734 · Phase 2 · registry result, not featured evidence
66.7%Carfilzomib - Mild RI
NCT00721734 · Phase 2 · registry result, not featured evidence
100%Carfilzomib - Moderate RI
NCT00721734 · Phase 2 · registry result, not featured evidence
41.7%Carfilzomib - Normal RF
NCT00721734 · Phase 2 · registry result, not featured evidence
75%Carfilzomib - Severe RI
NCT00721734 · Phase 2 · registry result, not featured evidence
33.3%56mg/m2/Dose
NCT02937571 · Phase 1/2 · registry result, not featured evidence
0%45mg/m2/Dose
NCT02937571 · Phase 1/2 · registry result, not featured evidence
65.2%MTD: Carfilzomib
NCT02937571 · Phase 1/2 · registry result, not featured evidence
—Dose Level 0
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 1
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
100%Dose Level 0
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
33.3%Dose Level 1
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
66.7%Dose Level 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
50%Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
45.7%Phase 2
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
—Dose Level 3
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
16.7%88 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
26.7%70 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
39.3%70 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
0%56 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
33.3%45 mg/m²
NCT01677858 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
a
diarrhoea 43.4%
anaemia 42.3%
neutropenia 40.1%
NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3
show 62 more results
anaemia 56.1% (placebo 47.1%)
thrombocytopenia 36.9% (placebo 28.1%)
pyrexia 26.1% (placebo 18.3%)
NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3
infusion related reaction 45.2%
upper respiratory tract infection 41.2%
diarrhoea 40.7%
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
anaemia 42.3%
diarrhoea 36.1%
fatigue 32.2%
NCT01568866 · Phase 3
20/70 mg/m² once weekly
anaemia 29%
hypertension 24.4%
pyrexia 23.1%
NCT02412878 · Phase 3 · combination
20/27 mg/m² twice weekly
anaemia 31.1%
diarrhoea 21.7%
hypertension 20.9%
NCT02412878 · Phase 3 · combination
thrombocytopenia 38.6%
anaemia 36.7%
hypertension 36.7%
NCT03158688 · Phase 3 · combination
thrombocytopenia 56.7%
anaemia 44.8%
constipation 44.8%
NCT03412565 · Phase 2 · combination
peripheral sensory neuropathy 41.8%
constipation 38.8%
neutropenia 37.3%
NCT03412565 · Phase 2 · combination
thrombocytopenia 51.5%
anaemia 37.9%
hypertension 34.8%
NCT03412565 · Phase 2 · combination
neutropenia 67.7%
diarrhoea 49.2%
anaemia 40%
NCT03412565 · Phase 2 · combination
20/70 mg/m²
pyrexia 71.4%
blood creatinine increased 57.1%
chills 57.1%
NCT00531284 · Phase 1/2
20/70 mg/m²
fatigue 100%
thrombocytopenia 100%
anaemia 50%
NCT00531284 · Phase 1/2
20/70 mg/m²
nausea 54.5%
fatigue 45.5%
anaemia 27.3%
NCT00531284 · Phase 1/2
20/56 mg/m²
pyrexia 100%
asthenia 66.7%
cough 66.7%
NCT00531284 · Phase 1/2
20/56 mg/m² + Dex
fatigue 62.5%
pyrexia 50%
upper respiratory tract infection 50%
NCT00531284 · Phase 1/2 · combination
20/56 mg/m²
pyrexia 50%
anaemia 40%
constipation 40%
NCT00531284 · Phase 1/2
20/56 mg/m²
fatigue 58.3%
nausea 54.2%
pyrexia 54.2%
NCT00531284 · Phase 1/2
20/45 mg/m²
fatigue 100%
blood creatinine increased 66.7%
cancer pain 66.7%
NCT00531284 · Phase 1/2
20/45 mg/m² + Dex
fatigue 64.3%
cough 57.1%
upper respiratory tract infection 50%
NCT00531284 · Phase 1/2 · combination
20/45 mg/m²
chills 50%
fatigue 50%
hypoaesthesia 50%
NCT00531284 · Phase 1/2
45 mg/m²
fatigue 57.1%
nausea 57.1%
vomiting 57.1%
NCT00531284 · Phase 1/2
20/36 mg/m²
fatigue 75%
nausea 75%
anaemia 50%
NCT00531284 · Phase 1/2
20/36 mg/m² Bolus
asthenia 57.1%
headache 57.1%
nausea 57.1%
NCT00531284 · Phase 1/2
36 mg/m²
chest wall pain 33.3%
dyspnoea 33.3%
nausea 33.3%
NCT00531284 · Phase 1/2
20/36 mg/m² Bolus
fatigue 58.5%
nausea 43.1%
anorexia 40%
NCT00531284 · Phase 1/2
20/27 mg/m² Bolus
back pain 50%
fatigue 50%
abnormal dreams 25%
NCT00531284 · Phase 1/2
20 mg/m² Bolus
hypomagnesaemia 66.7%
anxiety 33.3%
constipation 33.3%
NCT00531284 · Phase 1/2
anaemia 73.9%
fatigue 69.6%
thrombocytopenia 50%
NCT00511238 · Phase 2
fatigue 48.9%
anaemia 45.9%
nausea 44.7%
NCT00511238 · Phase 2 · pooled
20/27 mg/m²
fatigue 54.3%
nausea 44.3%
anaemia 35.7%
NCT00530816 · Phase 2 · pooled
20 mg/m²
fatigue 62.9%
nausea 60%
vomiting 42.9%
NCT00530816 · Phase 2
20 mg/m²
fatigue 71.2%
nausea 54.2%
dyspnoea 49.2%
NCT00530816 · Phase 2
cough 42.3%
anaemia 36.5%
pyrexia 26.9%
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
cough 26.5%
diarrhoea 18.4%
hypertension 18.4%
NCT03934684 · Phase 4 · registry result, not featured evidence · combination
20/56 mg/m^2 once weekly
neutropenia 29.1%
anaemia 25.1%
hypertension 21.5%
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
20/27 mg/m^2 twice weekly
neutropenia 31.6%
hypertension 24.2%
anaemia 23.8%
NCT03859427 · Phase 3 · registry result, not featured evidence · combination
anaemia 61.8%
platelet count decreased 48.8%
upper respiratory tract infection 48.8%
NCT03029234 · Phase 3 · registry result, not featured evidence · combination
anaemia 35.4%
pyrexia 35.4%
nausea 35.2%
NCT01818752 · Phase 3 · registry result, not featured evidence · combination
fatigue 63%
diarrhea 45.7%
edema limbs 37%
NCT02969837 · Phase 2 · registry result, not featured evidence
lymphocyte count decreased 100%
hypoalbuminemia 93.3%
platelet count decreased 93.3%
NCT01402284 · Phase 2 · registry result, not featured evidence · combination
low-dose
anemia 59.1%
fatigue 59.1%
platelet count decreased 42.4%
NCT01903811 · Phase 2 · registry result, not featured evidence · combination
high-dose
anemia 66.7%
fatigue 57.9%
platelet count decreased 50.9%
NCT01903811 · Phase 2 · registry result, not featured evidence · combination
anemia 61.5%
hypertension 53.8%
platelet count decreased 53.8%
NCT01775553 · Phase 2 · registry result, not featured evidence
diarrhea 65.9%
nausea 59.1%
fatigue 54.5%
NCT01351623 · Phase 2 · registry result, not featured evidence
anaemia 62.5%
thrombocytopenia 62.5%
abdominal pain 50%
NCT00721734 · Phase 2 · registry result, not featured evidence
fatigue 75%
anaemia 58.3%
constipation 50%
NCT00721734 · Phase 2 · registry result, not featured evidence
anaemia 70%
fatigue 60%
nausea 60%
NCT00721734 · Phase 2 · registry result, not featured evidence
fatigue 75%
anaemia 50%
dyspnoea 50%
NCT00721734 · Phase 2 · registry result, not featured evidence
anaemia 62.5%
fatigue 50%
dyspnoea 37.5%
NCT00721734 · Phase 2 · registry result, not featured evidence
56mg/m2/Dose
anxiety 33.3%
hyperkalemia 33.3%
hypertension 33.3%
NCT02937571 · Phase 1/2 · registry result, not featured evidence
45mg/m2/Dose
lymphocyte count decreased 66.7%
skin infection 66.7%
alanine aminotransferase increased 33.3%
NCT02937571 · Phase 1/2 · registry result, not featured evidence
lymphocyte count decreased 73.9%
neutrophil count decreased 65.2%
white blood cell decreased 60.9%
NCT02937571 · Phase 1/2 · registry result, not featured evidence
Dose Level 0
anemia 100%
cd4 lymphocytes decreased 100%
lymphocyte count decreased 100%
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
Dose Level 1
anemia 100%
lymphocyte count decreased 100%
neutrophil count decreased 100%
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
Dose Level 2
hypotension 100%
lymphocyte count decreased 100%
neutrophil count decreased 100%
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
Dose Level 3
anemia 100%
platelet count decreased 100%
white blood cell decreased 100%
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
platelet count decreased 100%
lymphocyte count decreased 91.4%
white blood cell decreased 91.4%
NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination
88 mg/m²
headache 66.7%
fatigue 50%
insomnia 50%
NCT01677858 · Phase 1/2 · registry result, not featured evidence
70 mg/m²
upper respiratory tract infection 80%
diarrhoea 60%
fatigue 60%
NCT01677858 · Phase 1/2 · registry result, not featured evidence
70 mg/m²
fatigue 52.8%
nausea 40.4%
insomnia 32.6%
NCT01677858 · Phase 1/2 · registry result, not featured evidence
56 mg/m²
anaemia 66.7%
arthralgia 66.7%
cardiac murmur 66.7%
NCT01677858 · Phase 1/2 · registry result, not featured evidence
45 mg/m²
fatigue 100%
back pain 66.7%
diarrhoea 66.7%
NCT01677858 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 66 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Carfilzomib

PFS 26.3 vs 17.6 Lenalidomide and Dexamethasone (Rd) months
time to event · months
NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3
show 7 more results
3.7 vs 3.3 placebo months
NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3
NA vs 19.15 Carfilzomib + Dexamethasone months
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
NA vs 20.27 Carfilzomib + Dexamethasone months
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
35.65 vs 19.15 Carfilzomib + Dexamethasone months
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
41.66 vs 20.76 Carfilzomib + Dexamethasone months
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
18.7 vs 9.4 Bortezomib months
NCT01568866 · Phase 3 · combination
22.3 vs 22.1 Bortezomib, Melphalan, Prednisone months
NCT01818752 · Phase 3 · registry result, not featured evidence · combination
Overall Survival 48.3 vs 40.4 Lenalidomide and Dexamethasone (Rd) months
time to event · months
NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3
show 5 more results
10.2 vs 10 placebo months
NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3
NA vs 50.6 Carfilzomib + Dexamethasone months
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
47.6 vs 40 Bortezomib months
NCT01568866 · Phase 3 · combination
50.8 vs 43.6 Carfilzomib and Dexamethasone months
NCT03158688 · Phase 3 · combination
NA vs NA Bortezomib, Melphalan, Prednisone months
NCT01818752 · Phase 3 · registry result, not featured evidence · combination
ORR 87.1% (n=396) vs 66.7% (n=396) Lenalidomide and Dexamethasone (Rd)
responder rate · % of participants
NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3
show 4 more results
86.6% (n=179) vs 82.9% (n=123) Carfilzomib + Dexamethasone
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
76.9% (n=464) vs 62.6% (n=465) Bortezomib
NCT01568866 · Phase 3 · combination
84.3% (n=312) vs 74.7% (n=154) Carfilzomib and Dexamethasone
NCT03158688 · Phase 3 · combination
84.3% (n=478) vs 78.8% (n=477) Bortezomib, Melphalan, Prednisone
NCT01818752 · Phase 3 · registry result, not featured evidence · combination
Disease Control 92.7% (n=396) vs 87.1% (n=396) Lenalidomide and Dexamethasone (Rd)
responder rate · % of participants
NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3
Duration of Response 28.6 vs 21.2 Lenalidomide and Dexamethasone (Rd) months
time to event · months
NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3
show 4 more results
7.2 vs 9.5 placebo months
NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3
NA vs NA Carfilzomib + Dexamethasone months
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
21.3 vs 10.4 Bortezomib months
NCT01568866 · Phase 3 · combination
NA vs 16.6 Carfilzomib and Dexamethasone months
NCT03158688 · Phase 3 · combination
Duration of Disease Control 28.7 vs 18.9 Lenalidomide and Dexamethasone (Rd) months
time to event · months
NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3
ORR 19.1% (n=157) vs 11.4% (n=158) placebo
event count · % of participants
NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 · converted to % from 30 participants as posted
Clinical Benefit 31.2% (n=157) vs 20.9% (n=158) placebo
event count · % of participants
NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 · converted to % from 49 participants as posted
VGPR or Better 72.6% (n=179) vs 56.1% (n=123) Carfilzomib + Dexamethasone
responder rate · % of participants
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
VGPR or Better With MRD Negativity 29.6% (n=179) vs 13% (n=123) Carfilzomib + Dexamethasone
responder rate · % of participants
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more result
33.5% (n=179) vs 13.8% (n=123) Carfilzomib + Dexamethasone
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
Complete 44.1% (n=179) vs 28.5% (n=123) Carfilzomib + Dexamethasone
responder rate · % of participants
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
show 2 more results
28.5% (n=312) vs 10.4% (n=154) Carfilzomib and Dexamethasone
NCT03158688 · Phase 3 · combination
25.9% (n=478) vs 23.1% (n=477) Bortezomib, Melphalan, Prednisone
NCT01818752 · Phase 3 · registry result, not featured evidence · combination
Complete Response With MRD Negativity 26.3% (n=179) vs 12.2% (n=123) Carfilzomib + Dexamethasone
responder rate · % of participants
NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more result
12.8% (n=312) vs 1.9% (n=154) Carfilzomib and Dexamethasone @ 52wk
NCT03158688 · Phase 3 · combination

+ 118 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Carfilzomib's landscape · TQB3602's landscape